Study shows removing entire bladder in cancer patients increases chance of survival

Jul 11, 2018, 20:15 PM by Donna Ramirez


A nationwide study led by UTMB researchers has confirmed that for patients with bladder cancer,
removing the whole organ increases their chances of survival and is more cost effective than therapies that selectively target and remove cancerous tissue from the bladder. 

Last year, there were an estimated 79,000 new cases and 17,000 deaths from bladder cancer in the U.S., and the current recommended treatment for the disease is for patients to have their bladder and surrounding lymph nodes removed surgically in addition to undergoing chemotherapy.

This surgery is complex, and because bladder cancer patients are often older, many of them have health issues beyond the cancer. For this reason—in addition to health-related quality of life concerns—both health professionals and patients have sought other treatment strategies.

An increasing number of patients opt for a less-invasive treatment strategy that doesn’t involve removing the entire bladder. With this approach, a surgeon takes small samples of bladder tissue to locate cancerous sections and removes only the cancerous tissue. These patients also receive chemotherapy and radiation therapy.

“In this study, our analysis of data from 3,200 Medicare beneficiaries diagnosed with clinical stage II through IV bladder cancer found that removing the whole bladder at once improved survival rates,” said Dr. Stephen B. Williams, lead author and associate professor in UTMB’s Department of Surgery, Division of Urology. “We also summed up all Medicare health care expenditures from inpatient, outpatient and physician services within 30, 90 and 180 days of both treatment approaches, finding the complete bladder removal to be more cost-effective.”

The researchers found that in the U.S, the less-invasive therapy ended up costing $335 million more in one year when compared with complete bladder removal.

“These findings provide important insight on how to provide cancer care that is both appropriate and cost-effective treatment for patients who are candidates for either treatment,” said Williams.

Other authors of the study include UTMB’s Dr. Yong Shan, Usama Jazzar, Dr. Hemalkumar Mehta, Dr. Jacques Baillargeon, Dr. Anthony Senagore, Dr. Eduardo Orihuela, Dr. Douglas Tyler and Dr. Todd Swanson, as well as Jinhai Huo from the University of Florida and Ashish Kamat from The University of Texas MD Anderson Cancer Center.